Experience & History
Andrew has over 30 years of commercial experience in the Diagnostics and Life Sciences industry. His previous roles include Chief Commercial Officer at Novel Technologies Holdings Ltd (NTH), Chief Executive Officer and founder of EKF Molecular Diagnostics and a nonexecutive director for Arcis Biotechnology.
Prior to EKF, Andrew joined QIAGEN as Senior Director, Personalised Healthcare following the acquisition of the pioneering personalised healthcare company, DxS Ltd in 2009 where he was Commercial Director. His early career included roles at Amersham Biosciences (now GE Healthcare) and in preclinical research at SmithKlineBeecham (now GlaxoSmithKline).
CRISM Therapeutics
CRISM Therapeutics uses hot melt extrusion, injection moulding and 3D printing to improve the clinical performance of active pharmaceutical ingredients (APIs), through solubility enhancement, local drug delivery and personalised medicines. In collaboration with the University of Birmingham CRISM has developed ChemoSeed® a platform implantable drug delivery technology that improves the clinical performance of APIs used in cancer treatment by delivering them directly to their required site of action. The Company's first product is for the treatment of high grade glioma (brain tumour). CRISM Therapeutics is also responsible for the commercialisation of ChemoSeed, an implantable device designed to be implanted at the surgical margin of a brain tumour, improving the delivery of chemotherapy to the tumour margin while reducing systemic toxicities. This approach will improve the efficacy of brain tumour treatment, while reducing the onerous side effects on patients.
